Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s stock price traded up 5.6% during mid-day trading on Tuesday . The stock traded as high as $22.96 and last traded at $22.86. 35,754 shares were traded during trading, a decline of 56% from the average session volume of 81,862 shares. The stock had previously closed at $21.65.
Analysts Set New Price Targets
PHVS has been the subject of several research analyst reports. Guggenheim initiated coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 price target for the company. JMP Securities lowered their price target on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research report on Wednesday, August 13th. Wedbush reaffirmed an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Zacks Research raised Pharvaris from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Finally, Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Pharvaris currently has an average rating of "Moderate Buy" and an average price target of $34.00.
Read Our Latest Stock Report on Pharvaris
Pharvaris Trading Up 4.9%
The firm has a 50 day simple moving average of $21.37 and a 200 day simple moving average of $17.78. The firm has a market capitalization of $1.21 billion, a PE ratio of -6.86 and a beta of -2.80.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.07). Research analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current year.
Hedge Funds Weigh In On Pharvaris
Several hedge funds and other institutional investors have recently modified their holdings of the company. Soleus Capital Management L.P. raised its holdings in Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after purchasing an additional 216,483 shares during the period. Octagon Capital Advisors LP grew its position in shares of Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after purchasing an additional 157,530 shares in the last quarter. Northern Trust Corp grew its position in shares of Pharvaris by 483.9% during the fourth quarter. Northern Trust Corp now owns 91,932 shares of the company's stock valued at $1,762,000 after purchasing an additional 76,188 shares in the last quarter. TFG Asset Management GP Ltd grew its position in shares of Pharvaris by 48.1% during the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after purchasing an additional 61,105 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Pharvaris during the fourth quarter valued at about $853,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
